治疗药物监测指导阿达木单抗治疗慢性非感染性葡萄膜炎的回顾性研究
该回顾性研究评估了阿达木单抗治疗慢性非感染性葡萄膜炎时进行治疗药物监测的相关性。共44例患者接受监测,应答者血清阿达木单抗水平显著高于无应答者(p=0.0004)。监测指导了注射频率调整、剂量增加或换药,多数调整后病情改善,支持个体化优化治疗。
要点
- 应答者阿达木单抗谷浓度显著高于无应答者(p=0.0004)
- 抗阿达木单抗抗体阳性者多为无应答者,需换用戈利木单抗或甲氨蝶呤
- 基于监测调整治疗(增频、加量、换药)后87%无应答者病情改善
核心结论
- 阿达木单抗治疗药物监测有助于为慢性非感染性葡萄膜炎患者提供个体化、优化的治疗方案(包括用药频率和药物类型)。
研究设计与样本
- 回顾性研究,纳入2003年6月至2019年7月间接受阿达木单抗治疗且至少完成一次血清阿达木单抗浓度和抗阿达木单抗抗体检测的慢性非感染性葡萄膜炎患者,共44例,对应79次治疗药物监测。
主要发现
- 79次监测中,48次(61%)来自应答者,11次(14%)来自原发无应答者,20次(25%)来自继发无应答者。
- 应答者阿达木单抗水平显著高于无应答者(p=0.0004)。
- 6例患者可检测到抗阿达木单抗抗体,其中原发无应答2例、继发无应答3例、应答者1例。
- 5例无应答且免疫化患者换用戈利木单抗或甲氨蝶呤。
- 无应答者中,监测导致12/31(38%)增加注射频率、1/31(3%)增加剂量、10/31(32%)换药(1例缺失数据),7/31(22%)未调整生物制剂仅调整局部或口服激素。
关键数值与推荐
- 无应答者治疗调整后31例中24例有疗效评估,87%观察到改善。
- 应答者中阿达木单抗水平高于疗效阈值的31例中,15例(48.4%)降低注射频率,其中12/15(80%)未复发。
临床怎么用
- 对慢性非感染性葡萄膜炎患者使用阿达木单抗时,可依据血清药物浓度和抗抗体检测结果调整注射频率、剂量或更换生物制剂,以实现个体化治疗。
局限性
- 回顾性研究设计,样本量有限(44例患者),部分数据缺失(如1例治疗调整缺失)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the relevance of therapeutic drug monitoring (TDM) of adalimumab (ADA) treatment for the control of intraocular inflammation and treatment adjustment in chronic non-infectious uveitis (CNIU). METHODS: Retrospective study of CNIU patients treated with ADA and for whom at least one dosage of serum ADA level and an antibodies against ADA (AAA) serology were performed, between June 2003 and July 2019. RESULTS: A total of 44 ADA-treated patients benefited from a TDM. A total of 48/79 (61%) TDM were performed in responders, 11/79 (14%) in primary non-responders, and 20/79 (25%) in secondary non-responders. Responders had significantly higher ADA levels than non-responders (p=0.0004). AAA were detectable in six patients, they were primary non-responders (n=2), secondary non-responders (n=3) or responders (n=1). In the five non-responders and immunised patients, ADA was switched (to golimumab or methotrexate). Among non-responders, TDM led to an increased frequency of injections 12/31 (38%), increased dose 1/31 (3%) and switch of treatment 10/31 (32%) (one missing data). No modification of biotherapy was performed 7/31 (22%) and only local or oral corticotherapy was adjusted. In 24/31 cases of therapeutic adjustment in non-responders, an improvement was observed in 87% of cases. Among responders for whom the ADA level was above the efficacy threshold, the frequency of injections was decreased for 15/31 (48.4%) cases and no relapse was observed in 12/15 (80%) cases. CONCLUSION: TDM of ADA treatment proved relevant to provide CNIU patients with a personalised and optimised treatment course (in terms of frequency and type of drug).
引用
- Sejournet L, Kerever S, Mathis T, et al. Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study. Br J Ophthalmol. 2021. PMID: 33875451. doi:10.1136/bjophthalmol-2021-319072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。